In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

por Gambichler, Thilo, Harnischfeger, Friederike, Skrygan, Marina, Majchrzak-Stiller, Britta, Buchholz, Marie, Müller, Thomas, Braumann, Chris
Publicado 2023

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Re...

por Buchholz, Marie, Strotmann, Johanna, Majchrzak-Stiller, Britta, Hahn, Stephan, Peters, Ilka, Horn, Julian, Müller, Thomas, Höhn, Philipp, Uhl, Waldemar, Braumann, Chris
Publicado 2022

Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study

por Baron, Claudia, Buchholz, Marie, Majchrzak-Stiller, Britta, Peters, Ilka, Fein, Daniel, Müller, Thomas, Uhl, Waldemar, Höhn, Philipp, Strotmann, Johanna, Braumann, Chris
Publicado 2022

GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells

por Majchrzak‐Stiller, Britta, Buchholz, Marie, Peters, Ilka, Waschestjuk, Daniel, Strotmann, Johanna, Höhn, Philipp, Hahn, Stephan, Braumann, Chris, Uhl, Waldemar, Müller, Thomas, Möhler, Hanns
Publicado 2023

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results

por Gambichler, Thilo, Majchrzak-Stiller, Britta, Peters, Ilka, Becker, Jürgen C., Strotmann, Johanna, Abu Rached, Nessr, Müller, Thomas, Uhl, Waldemar, Buchholz, Marie, Braumann, Chris
Publicado 2023